Bristol-Myers Squibb (BMY - Free Report) closed the most recent trading day at $53.08, moving -0.32% from the previous trading session. This change was narrower than the S&P 500's 2.33% loss on the day. Meanwhile, the Dow lost 2.24%, and the Nasdaq, a tech-heavy index, lost 3.05%.
Prior to today's trading, shares of the biopharmaceutical company had gained 0.83% over the past month. This has lagged the Medical sector's gain of 1.22% and outpaced the S&P 500's loss of 1.93% in that time.
Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be January 24, 2019. In that report, analysts expect BMY to post earnings of $0.84 per share. This would mark year-over-year growth of 23.53%. Our most recent consensus estimate is calling for quarterly revenue of $5.99 billion, up 9.85% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.87 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +28.57% and +8.68%, respectively.
It is also important to note the recent changes to analyst estimates for BMY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY currently has a Zacks Rank of #1 (Strong Buy).
Digging into valuation, BMY currently has a Forward P/E ratio of 13.76. This represents a discount compared to its industry's average Forward P/E of 14.58.
Also, we should mention that BMY has a PEG ratio of 1.48. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.